DKSH expands into Middle East with $390 million healthcare deal

DKSH is paying US$390 million to establish its healthcare business in a new region. The Zurich based trading and services group announced on Monday, October 19, 2026, that its Healthcare division will acquire all shares in Newbridge Pharmaceuticals, a Dubai based distributor specialising in medicines for rare and complex diseases.

The transaction gives DKSH an operating base across the Middle East and North Africa, a region where it has not previously had a footprint through its Healthcare division. Newbridge operates in 14 markets, including the two most important markets identified by DKSH, Saudi Arabia and the United Arab Emirates.

For the Swiss group, the deal extends a healthcare strategy built in the Asia Pacific region into a market where pharmaceutical companies often rely on specialist partners to secure regulatory access, launch products and reach patients. Newbridge provides those services alongside medicine distribution.

DKSH expects the acquisition to support revenue growth, its adjusted EBIT margin and earnings per share from completion. The transaction remains subject to regulatory approval and is expected to close by the end of the first quarter of 2027.

Newbridge brings more than 300 employees and a specialist medicines platform to DKSH. Founded in 2010, the company focuses on oncology, neurology, immunology and gastroenterology, fields that require specialised commercial, regulatory and distribution capabilities.

Its business extends beyond moving products through the supply chain. Newbridge supports pharmaceutical companies with product launches and market access, helping manufacturers introduce therapies into regional healthcare systems. That service model aligns with the outsourced marketing activities that DKSH chief executive Stefan Butz described as a major growth driver in recent years.

The acquisition also gives DKSH an established management team. Newbridge’s current leadership is expected to remain after the transaction, preserving local expertise as the business joins the Swiss group. That continuity could help DKSH navigate the different regulatory systems and commercial conditions across the 14 markets in which Newbridge operates.

The emphasis on rare and complex diseases is significant for the combined business. Such medicines generally require more than conventional wholesale distribution. Companies need specialist education, market access work and coordinated support for launches, all of which form part of Newbridge’s existing offer.

DKSH forecasts about US$385 million in Newbridge revenue for 2027. The projection comes with an EBITDA margin in the high single digit percentage range, offering investors an early view of the business contribution DKSH expects from the acquisition.

The purchase price is only slightly above that projected annual revenue, although revenue and acquisition value measure different things and cannot be treated as a direct valuation multiple. DKSH has not disclosed a more detailed breakdown of Newbridge’s profitability or the precise debt terms supporting the transaction.

The Swiss group said debt financing will leave sufficient financial flexibility for further acquisitions. It also said its current dividend policy will remain unchanged. Those assurances place the deal within DKSH’s broader expansion programme while signalling that management does not expect the purchase to require a change in shareholder distributions.

The financial impact will depend on the timing of completion, regulatory approvals and the integration of Newbridge into DKSH’s Healthcare division. DKSH expects a positive effect on revenue growth, adjusted EBIT margin and earnings per share from the date the transaction closes.

The deal gives a Swiss company direct exposure to healthcare markets from Riyadh to Dubai and beyond. DKSH has long operated as a market expansion partner for companies that need distribution, marketing and commercial support. Its Healthcare division has until now concentrated on Asia Pacific, making the Newbridge purchase a material geographic shift.

For Swiss pharmaceutical manufacturers, the expanded platform could offer another route into Middle Eastern and North African markets. DKSH will gain Newbridge’s regional relationships, local employees and experience with product launches and market access. The company has not said which pharmaceutical clients or products will transfer through the acquisition.

The next milestone is regulatory review. DKSH expects the transaction to close by the end of March 2027 if approvals arrive on schedule. Newbridge’s management team is set to stay, which should support continuity during the transition.

The acquisition also keeps Switzerland’s international trading sector tied to the practical infrastructure of global healthcare. Distribution networks, regulatory knowledge and launch services can determine whether specialised treatments move from a manufacturer into hospitals and pharmacies. DKSH’s next test will be to integrate that regional capability while maintaining the financial discipline promised to investors.